5,6-Difluoroindole-2-Carboxylic Acid

We are 5,6-Difluoroindole-2-Carboxylic Acid CAS:169674-35-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:5,6-Difluoroindole-2-Carboxylic Acid
CAS.NO:169674-35-5
Synonyms:5,6-Difluoroindole-2-Carboxylic Acid
5,6-difluoro-1H-indole-2-carboxylic acid
 
Physical and Chemical Properties:
Density 1.6±0.1 g/cm3
Boiling Point 427.4±40.0 °C at 760 mmHg
Molecular Formula C9H5F2NO2
Molecular Weight 197.138
Flash Point 212.3±27.3 °C
Vapour Pressure 0.0±1.1 mmHg at 25°C
Index of Refraction 1.662
 
Specification:
Appearance:Tan powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.

5,6-Difluoroindole-2-Carboxylic Acid


Related News: The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.Cyclopentyl methyl ether CAS:5614-37-9 TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.N-methylaniline CAS:100-61-8 In terms of business, the industrial business increased by 7.97% year-on-year, while the revenue from the trading business shrank to a certain extent. The growth rate of industrial business was significantly slower than 24% in the first half of the year, showing that the growth rate of industrial business was lower in the third quarter, which was also the main reason for the decline in the company’s operating income in the third quarter. The company’s industrial business is mainly pesticide intermediates, accounting for about 85%. The scale of the pesticide intermediate business is large and the base is high, which is putting pressure on growth.2213-63-0 The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.

Related Products
Product Name
2-Chloro-4-fluorobenzoic acid View Details
4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine View Details
3-Fluoro-4-nitrobenzoic acid View Details
(2S,3S)-1,2-Epoxy-3-(Cbz-amino)-4-phenylbutane manufacturer 5-Methoxy-3-indolecarboxylic acid manufacturer HC Blue 12 manufacturer 2-Cyano-4-fluorobenzoic acid manufacturer Cyclohexylmethyl bromide manufacturer